Brought to you by 
QUT bluebox and MDxHealth ally for oral cancer liquid biopsy test
06 Jul 2017
Executive Summary
MDxHealth SA and QUT bluebox Pty. Ltd. (the commercialization arm of Queensland University of Technology (QUT) partnered to develop an epigenetic liquid biopsy assay for the early diagnosis of oral cancer.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
QUT bluebox and MDxHealth ally for oral cancer liquid biopsy test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice